Latest Conference Articles

Squalamine lactate, a topical eye drop, is studied as an add-on to anti-VEGF therapy to improve visual function.

An average 7,000 steps per day can cut glaucoma risk by up to 73%, researchers found.

The distractive spots floating through fields of vision may have finally met their match.

Researchers found racial and ethnic disparities in sites and types of injuries sustained in gunfire injuries to patients' eyes.

The multi-targeted inhibitor, a non-invasive eye drop, acts in a different way of treating the chronic disease.

The diagnostics of the disease is not only important for the initial evaluation, but also etiology and long-term management.

A study of Florida-based Veterans Affairs hospitals found trends among ocular conditions and chronic pain conditions.

As new diagnoses appear, etiology is understood better and treated better, resulting in a decrease of prevalence rates.

The smarthpone app Checkup is a preferred visual acuity test to the Amsler grid, according to study.

A study sub-analysis showed the anti-VEGF treatment maintained efficacy over longer intervals in a majority of patients.

A third review of TrueTear from Allergan showed the device is safe and efficacious in patients with dry eye.

A review of over 13,000 newly-diagnosed DME patients found that about 75% received no treatment in the first 28 days since diagnosis.

Vision loss patients may be 3 times as likely to suffer from major depressive symptoms than the general population.

The demand for diabetic-based health care is growing, and the future of imaging and treatment must follow guidelines.

The study compared bevacizumab, ranibizumab, and aflibercept for nAMD patients' eyes.

Studies based on data from the world's largest clinical specialty database corrected commonly-perceived trends in ophthalmology.

The grant will provide $35,000 to 6 inidivual researchers, who will use the 41 million-plus patient database IRIS Registry.

Luxturna, an injection therapy, helped genetic vision-loss patients navigate mazes in a phase 3 trial.

The biologic agent has shown efficacy in reducing asthma exacerbations and improving patient quality of life.

Robert Zivadinov, MD, discussed how the results of the TOPIC study will impact clinical practice for those specializing in mutliple sclerosis, and what doctors should look for while caring for patients with MS.

Gordon L. Yung, MD, FCCP, explains the right patient perspective of the antifibrotic therapy.

Ruth Ann Marrie, MD, PhD, FRCP, discussed what it's like to treat patients with multiple sclerosis from a team-based approach, as well as what needs to be done to address the issues faced by patients with MS that also have comorbidities.

Robert Zivadinov, MD, discussed the remaining question about Aubagio's mechanism of action after collecting data from the TOPIC study.

Almost 500 patients were split into 4 dosing groups for JZP-110.

Researchers studied recently-referred COPD patients and what attributes put them at risk for poor inhaler device technique.

Attendees at MS Paris 2017 discussed the biggest unmet needs in treating multiple sclerosis.

Many of the symptoms of VTE are normal during pregnancy, and it's difficult to find a suitable population to test out new diagnostic and therapeutic methods.

There's a medical emergency in one in every 604 flights. Here's what doctors need to know so they can handle them appropriately.

John Corboy, MD, discussed how there is a lack of knowledge on when and why to stop using disease-modifying therapies with MS patients.

Two consecutive CHEST studies showed combination therapy's expanding portfolio.